Bayer supplies Xofigo to United Lincolnshire hospitals for prostate cancer
- United Lincolnshire Teaching Hospitals NHS Trust
- East Midlands
- Direct
- 31 December 2025 to 30 December 2027
United Lincolnshire Teaching Hospitals NHS Trust buys Xofigo from Bayer to treat patients with prostate cancer. Xofigo, or radium-223 dichloride, is a radiopharmaceutical that the trust uses in nuclear medicine.
The trust awarded the work directly to Bayer, without running a competition. The two-year contract, worth £105,600, runs from December 2025 to December 2027.
Contract ends December 2027
- What
- Radiopharmaceuticals and contrast media
- Supplier
- Bayer
- Value
- £105,600
- How it was bought
- Direct
- Dates and next
- Dec 2025 to Dec 2027